nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—DRD2—nicotine dependence	0.698	1	CbGaD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.00817	0.0599	CbGpPWpGaD
L-DOPA—DRD5—Dopamine receptors—DRD2—nicotine dependence	0.00692	0.0507	CbGpPWpGaD
L-DOPA—PSIP1—cardiovascular system—nicotine dependence	0.00653	0.157	CbGeAlD
L-DOPA—Hoarseness—Varenicline—nicotine dependence	0.00608	0.0495	CcSEcCtD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.00527	0.0386	CbGpPWpGaD
L-DOPA—DRD4—Dopamine receptors—DRD2—nicotine dependence	0.00511	0.0375	CbGpPWpGaD
L-DOPA—PSIP1—midbrain—nicotine dependence	0.0051	0.123	CbGeAlD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.00474	0.0347	CbGpPWpGaD
L-DOPA—DRD1—Dopamine receptors—DRD2—nicotine dependence	0.0046	0.0337	CbGpPWpGaD
L-DOPA—DRD3—Dopamine receptors—DRD2—nicotine dependence	0.00454	0.0333	CbGpPWpGaD
L-DOPA—Libido increased—Varenicline—nicotine dependence	0.0044	0.0358	CcSEcCtD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.00429	0.0315	CbGpPWpGaD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.00421	0.0309	CbGpPWpGaD
L-DOPA—Delusion—Varenicline—nicotine dependence	0.00378	0.0308	CcSEcCtD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.00378	0.0277	CbGpPWpGaD
L-DOPA—Mania—Varenicline—nicotine dependence	0.00368	0.0299	CcSEcCtD
L-DOPA—Extrapyramidal disorder—Varenicline—nicotine dependence	0.00355	0.0289	CcSEcCtD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.00343	0.0252	CbGpPWpGaD
L-DOPA—Mydriasis—Varenicline—nicotine dependence	0.00336	0.0273	CcSEcCtD
L-DOPA—SLC7A5—cardiovascular system—nicotine dependence	0.00333	0.0802	CbGeAlD
L-DOPA—Dysphonia—Varenicline—nicotine dependence	0.00325	0.0265	CcSEcCtD
L-DOPA—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.00322	0.0236	CbGpPWpGaD
L-DOPA—PSIP1—brain—nicotine dependence	0.0032	0.0771	CbGeAlD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.00305	0.0224	CbGpPWpGaD
L-DOPA—DDC—midbrain—nicotine dependence	0.00291	0.07	CbGeAlD
L-DOPA—DDC—Nicotine Activity on Dopaminergic Neurons—DRD2—nicotine dependence	0.00279	0.0205	CbGpPWpGaD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.00271	0.0199	CbGpPWpGaD
L-DOPA—Musculoskeletal pain—Varenicline—nicotine dependence	0.00271	0.022	CcSEcCtD
L-DOPA—DRD4—brain—nicotine dependence	0.00267	0.0642	CbGeAlD
L-DOPA—SLC7A5—midbrain—nicotine dependence	0.0026	0.0627	CbGeAlD
L-DOPA—Salivary hypersecretion—Varenicline—nicotine dependence	0.0026	0.0211	CcSEcCtD
L-DOPA—Nightmare—Varenicline—nicotine dependence	0.00258	0.021	CcSEcCtD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.00249	0.0183	CbGpPWpGaD
L-DOPA—Euphoric mood—Varenicline—nicotine dependence	0.0023	0.0187	CcSEcCtD
L-DOPA—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.00228	0.0167	CbGpPWpGaD
L-DOPA—Sleep disorder—Varenicline—nicotine dependence	0.00224	0.0183	CcSEcCtD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.00221	0.0162	CbGpPWpGaD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.00219	0.0161	CbGpPWpGaD
L-DOPA—Disorientation—Varenicline—nicotine dependence	0.00217	0.0177	CcSEcCtD
L-DOPA—DRD1—midbrain—nicotine dependence	0.00214	0.0514	CbGeAlD
L-DOPA—SLC7A8—brain—nicotine dependence	0.00211	0.0508	CbGeAlD
L-DOPA—Hot flush—Varenicline—nicotine dependence	0.00208	0.0169	CcSEcCtD
L-DOPA—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.00208	0.0152	CbGpPWpGaD
L-DOPA—Menopausal symptoms—Varenicline—nicotine dependence	0.00206	0.0168	CcSEcCtD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.00199	0.0146	CbGpPWpGaD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.00195	0.0143	CbGpPWpGaD
L-DOPA—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00194	0.0158	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00193	0.0157	CcSEcCtD
L-DOPA—Psychotic disorder—Varenicline—nicotine dependence	0.0019	0.0154	CcSEcCtD
L-DOPA—DRD3—brain—nicotine dependence	0.00187	0.0451	CbGeAlD
L-DOPA—Urinary retention—Varenicline—nicotine dependence	0.00185	0.015	CcSEcCtD
L-DOPA—DDC—brain—nicotine dependence	0.00183	0.044	CbGeAlD
L-DOPA—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.00178	0.013	CbGpPWpGaD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.00177	0.013	CbGpPWpGaD
L-DOPA—DRD5—brain—nicotine dependence	0.00176	0.0423	CbGeAlD
L-DOPA—Cramp muscle—Varenicline—nicotine dependence	0.00175	0.0142	CcSEcCtD
L-DOPA—Nasopharyngitis—Varenicline—nicotine dependence	0.00174	0.0141	CcSEcCtD
L-DOPA—Gastritis—Varenicline—nicotine dependence	0.00172	0.014	CcSEcCtD
L-DOPA—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.00169	0.0124	CbGpPWpGaD
L-DOPA—Dysphagia—Varenicline—nicotine dependence	0.00168	0.0137	CcSEcCtD
L-DOPA—SLC7A5—brain—nicotine dependence	0.00164	0.0394	CbGeAlD
L-DOPA—Angina pectoris—Varenicline—nicotine dependence	0.00164	0.0133	CcSEcCtD
L-DOPA—DRD4—Nicotine Activity on Dopaminergic Neurons—DRD2—nicotine dependence	0.00162	0.0119	CbGpPWpGaD
L-DOPA—Pollakiuria—Varenicline—nicotine dependence	0.00155	0.0126	CcSEcCtD
L-DOPA—DRD5—Monoamine GPCRs—DRD2—nicotine dependence	0.00153	0.0112	CbGpPWpGaD
L-DOPA—Weight increased—Varenicline—nicotine dependence	0.00153	0.0124	CcSEcCtD
L-DOPA—Depression—Varenicline—nicotine dependence	0.00149	0.0121	CcSEcCtD
L-DOPA—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.00149	0.0109	CbGpPWpGaD
L-DOPA—Acute coronary syndrome—Varenicline—nicotine dependence	0.00148	0.012	CcSEcCtD
L-DOPA—Myocardial infarction—Varenicline—nicotine dependence	0.00147	0.0119	CcSEcCtD
L-DOPA—DRD3—Nicotine Activity on Dopaminergic Neurons—DRD2—nicotine dependence	0.00144	0.0106	CbGpPWpGaD
L-DOPA—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00141	0.0104	CbGpPWpGaD
L-DOPA—DRD2—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.00135	0.00992	CbGpPWpGaD
L-DOPA—DRD1—brain—nicotine dependence	0.00134	0.0323	CbGeAlD
L-DOPA—Hypoaesthesia—Varenicline—nicotine dependence	0.00134	0.0109	CcSEcCtD
L-DOPA—Hallucination—Varenicline—nicotine dependence	0.00134	0.0109	CcSEcCtD
L-DOPA—Urinary tract disorder—Varenicline—nicotine dependence	0.00133	0.0108	CcSEcCtD
L-DOPA—Urethral disorder—Varenicline—nicotine dependence	0.00132	0.0107	CcSEcCtD
L-DOPA—DRD5—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00129	0.00943	CbGpPWpGaD
L-DOPA—DRD2—midbrain—nicotine dependence	0.00126	0.0304	CbGeAlD
L-DOPA—Arrhythmia—Varenicline—nicotine dependence	0.0012	0.00977	CcSEcCtD
L-DOPA—Mental disorder—Varenicline—nicotine dependence	0.00118	0.00958	CcSEcCtD
L-DOPA—DRD4—Hypothetical Network for Drug Addiction—DRD2—nicotine dependence	0.00116	0.00848	CbGpPWpGaD
L-DOPA—Flatulence—Varenicline—nicotine dependence	0.00115	0.00938	CcSEcCtD
L-DOPA—Dysgeusia—Varenicline—nicotine dependence	0.00115	0.00932	CcSEcCtD
L-DOPA—DDC—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00114	0.00835	CbGpPWpGaD
L-DOPA—Back pain—Varenicline—nicotine dependence	0.00113	0.00921	CcSEcCtD
L-DOPA—DRD4—Monoamine GPCRs—DRD2—nicotine dependence	0.00113	0.00828	CbGpPWpGaD
L-DOPA—Muscle spasms—Varenicline—nicotine dependence	0.00112	0.00915	CcSEcCtD
L-DOPA—Vision blurred—Varenicline—nicotine dependence	0.0011	0.00897	CcSEcCtD
L-DOPA—Tremor—Varenicline—nicotine dependence	0.0011	0.00892	CcSEcCtD
L-DOPA—Ill-defined disorder—Varenicline—nicotine dependence	0.00109	0.00883	CcSEcCtD
L-DOPA—Anaemia—Varenicline—nicotine dependence	0.00108	0.0088	CcSEcCtD
L-DOPA—Agitation—Varenicline—nicotine dependence	0.00108	0.00875	CcSEcCtD
L-DOPA—Angioedema—Varenicline—nicotine dependence	0.00107	0.0087	CcSEcCtD
L-DOPA—Malaise—Varenicline—nicotine dependence	0.00106	0.00859	CcSEcCtD
L-DOPA—Syncope—Varenicline—nicotine dependence	0.00105	0.00854	CcSEcCtD
L-DOPA—DRD1—Hypothetical Network for Drug Addiction—DRD2—nicotine dependence	0.00104	0.00764	CbGpPWpGaD
L-DOPA—Palpitations—Varenicline—nicotine dependence	0.00103	0.00841	CcSEcCtD
L-DOPA—Loss of consciousness—Varenicline—nicotine dependence	0.00103	0.00837	CcSEcCtD
L-DOPA—Cough—Varenicline—nicotine dependence	0.00102	0.00831	CcSEcCtD
L-DOPA—DRD1—Monoamine GPCRs—DRD2—nicotine dependence	0.00102	0.00745	CbGpPWpGaD
L-DOPA—Convulsion—Varenicline—nicotine dependence	0.00101	0.00825	CcSEcCtD
L-DOPA—Hypertension—Varenicline—nicotine dependence	0.00101	0.00822	CcSEcCtD
L-DOPA—DRD3—Monoamine GPCRs—DRD2—nicotine dependence	0.001	0.00735	CbGpPWpGaD
L-DOPA—Chest pain—Varenicline—nicotine dependence	0.000996	0.0081	CcSEcCtD
L-DOPA—Anxiety—Varenicline—nicotine dependence	0.000993	0.00808	CcSEcCtD
L-DOPA—Discomfort—Varenicline—nicotine dependence	0.000984	0.00801	CcSEcCtD
L-DOPA—Dry mouth—Varenicline—nicotine dependence	0.000974	0.00793	CcSEcCtD
L-DOPA—Oedema—Varenicline—nicotine dependence	0.000955	0.00777	CcSEcCtD
L-DOPA—DRD4—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000949	0.00696	CbGpPWpGaD
L-DOPA—Shock—Varenicline—nicotine dependence	0.000939	0.00764	CcSEcCtD
L-DOPA—Thrombocytopenia—Varenicline—nicotine dependence	0.000935	0.00761	CcSEcCtD
L-DOPA—Hyperhidrosis—Varenicline—nicotine dependence	0.000923	0.00751	CcSEcCtD
L-DOPA—Anorexia—Varenicline—nicotine dependence	0.00091	0.00741	CcSEcCtD
L-DOPA—Hypotension—Varenicline—nicotine dependence	0.000892	0.00726	CcSEcCtD
L-DOPA—Insomnia—Varenicline—nicotine dependence	0.000864	0.00703	CcSEcCtD
L-DOPA—DRD1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000854	0.00626	CbGpPWpGaD
L-DOPA—Dyspnoea—Varenicline—nicotine dependence	0.000851	0.00693	CcSEcCtD
L-DOPA—Somnolence—Varenicline—nicotine dependence	0.000849	0.00691	CcSEcCtD
L-DOPA—DRD3—Amine ligand-binding receptors—DRD2—nicotine dependence	0.000843	0.00618	CbGpPWpGaD
L-DOPA—Dyspepsia—Varenicline—nicotine dependence	0.000841	0.00684	CcSEcCtD
L-DOPA—Decreased appetite—Varenicline—nicotine dependence	0.00083	0.00675	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Varenicline—nicotine dependence	0.000824	0.00671	CcSEcCtD
L-DOPA—Fatigue—Varenicline—nicotine dependence	0.000823	0.0067	CcSEcCtD
L-DOPA—Constipation—Varenicline—nicotine dependence	0.000817	0.00664	CcSEcCtD
L-DOPA—Pain—Varenicline—nicotine dependence	0.000817	0.00664	CcSEcCtD
L-DOPA—DRD2—brain—nicotine dependence	0.000793	0.0191	CbGeAlD
L-DOPA—Feeling abnormal—Varenicline—nicotine dependence	0.000787	0.0064	CcSEcCtD
L-DOPA—Gastrointestinal pain—Varenicline—nicotine dependence	0.000781	0.00635	CcSEcCtD
L-DOPA—DRD4—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00077	0.00565	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00076	0.00557	CbGpPWpGaD
L-DOPA—Urticaria—Varenicline—nicotine dependence	0.000759	0.00617	CcSEcCtD
L-DOPA—Abdominal pain—Varenicline—nicotine dependence	0.000755	0.00614	CcSEcCtD
L-DOPA—Hypersensitivity—Varenicline—nicotine dependence	0.000704	0.00572	CcSEcCtD
L-DOPA—DDC—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00069	0.00506	CbGpPWpGaD
L-DOPA—Asthenia—Varenicline—nicotine dependence	0.000685	0.00557	CcSEcCtD
L-DOPA—DRD3—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000684	0.00502	CbGpPWpGaD
L-DOPA—Pruritus—Varenicline—nicotine dependence	0.000676	0.0055	CcSEcCtD
L-DOPA—Diarrhoea—Varenicline—nicotine dependence	0.000653	0.00532	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000643	0.00471	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—TAS2R16—nicotine dependence	0.000632	0.00463	CbGpPWpGaD
L-DOPA—Dizziness—Varenicline—nicotine dependence	0.000631	0.00514	CcSEcCtD
L-DOPA—DDC—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00062	0.00455	CbGpPWpGaD
L-DOPA—Vomiting—Varenicline—nicotine dependence	0.000607	0.00494	CcSEcCtD
L-DOPA—Rash—Varenicline—nicotine dependence	0.000602	0.0049	CcSEcCtD
L-DOPA—Dermatitis—Varenicline—nicotine dependence	0.000601	0.00489	CcSEcCtD
L-DOPA—Headache—Varenicline—nicotine dependence	0.000598	0.00487	CcSEcCtD
L-DOPA—PSIP1—Disease—AKR1B10—nicotine dependence	0.000593	0.00435	CbGpPWpGaD
L-DOPA—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.000587	0.0043	CbGpPWpGaD
L-DOPA—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.000579	0.00424	CbGpPWpGaD
L-DOPA—Nausea—Varenicline—nicotine dependence	0.000567	0.00462	CcSEcCtD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000561	0.00411	CbGpPWpGaD
L-DOPA—Norepinephrine—DRD2—nicotine dependence	0.000546	0.518	CrCbGaD
L-DOPA—DRD2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.000524	0.00384	CbGpPWpGaD
L-DOPA—Dopamine—DRD2—nicotine dependence	0.000508	0.482	CrCbGaD
L-DOPA—CYP2D6—brain—nicotine dependence	0.000476	0.0115	CbGeAlD
L-DOPA—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.000476	0.00349	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—TAS2R16—nicotine dependence	0.000466	0.00342	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—DRD2—nicotine dependence	0.000459	0.00336	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00042	0.00308	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—TAS2R16—nicotine dependence	0.000414	0.00304	CbGpPWpGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000408	0.00299	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000373	0.00273	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00036	0.00264	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000357	0.00262	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00035	0.00256	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000325	0.00238	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—TAS2R16—nicotine dependence	0.000324	0.00238	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000324	0.00237	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00032	0.00234	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—TAS2R16—nicotine dependence	0.000317	0.00232	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000301	0.00221	CbGpPWpGaD
L-DOPA—DRD5—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000295	0.00216	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000289	0.00212	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000288	0.00211	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—FGD1—nicotine dependence	0.00028	0.00205	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000271	0.00199	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000268	0.00196	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000268	0.00196	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—OPRM1—nicotine dependence	0.000266	0.00195	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—DRD2—nicotine dependence	0.000266	0.00195	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000264	0.00193	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000258	0.00189	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—FGD1—nicotine dependence	0.000254	0.00187	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000253	0.00185	CbGpPWpGaD
L-DOPA—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000253	0.00185	CbGpPWpGaD
L-DOPA—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000249	0.00183	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000245	0.00179	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—DRD2—nicotine dependence	0.000239	0.00176	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—TAS2R16—nicotine dependence	0.000239	0.00175	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000237	0.00174	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—DRD2—nicotine dependence	0.000236	0.00173	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—DRD2—nicotine dependence	0.000235	0.00172	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000234	0.00172	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000232	0.0017	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000229	0.00168	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000221	0.00162	CbGpPWpGaD
L-DOPA—DRD4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000218	0.0016	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000215	0.00158	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—TAS2R16—nicotine dependence	0.000213	0.00156	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—DRD2—nicotine dependence	0.000209	0.00153	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—FGD1—nicotine dependence	0.000207	0.00152	CbGpPWpGaD
L-DOPA—DRD2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000205	0.0015	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—OPRM1—nicotine dependence	0.000197	0.00144	CbGpPWpGaD
L-DOPA—DRD1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000196	0.00144	CbGpPWpGaD
L-DOPA—DRD3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000194	0.00142	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—DRD2—nicotine dependence	0.000193	0.00141	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TAS2R16—nicotine dependence	0.000192	0.0014	CbGpPWpGaD
L-DOPA—DDC—Metabolism—CYP2A7—nicotine dependence	0.000188	0.00138	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—FGD1—nicotine dependence	0.000188	0.00138	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000187	0.00137	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—FGD1—nicotine dependence	0.000186	0.00136	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—FGD1—nicotine dependence	0.000184	0.00135	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000179	0.00131	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—OPRM1—nicotine dependence	0.000177	0.0013	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000175	0.00129	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—OPRM1—nicotine dependence	0.000175	0.00128	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—FGD1—nicotine dependence	0.000169	0.00124	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000168	0.00123	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—FGD1—nicotine dependence	0.000167	0.00122	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000166	0.00122	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000163	0.00119	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—OPRM1—nicotine dependence	0.000151	0.0011	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FGD1—nicotine dependence	0.00015	0.0011	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—DRD2—nicotine dependence	0.000142	0.00104	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TAS2R16—nicotine dependence	0.000141	0.00104	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—FGD1—nicotine dependence	0.000141	0.00103	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—OPRM1—nicotine dependence	0.000137	0.001	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—OPRM1—nicotine dependence	0.000134	0.00098	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKR1B10—nicotine dependence	0.000133	0.000973	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—DRD2—nicotine dependence	0.000128	0.000938	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—FGD1—nicotine dependence	0.000128	0.000936	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TAS2R16—nicotine dependence	0.000127	0.000933	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—DRD2—nicotine dependence	0.000126	0.000926	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TAS2R16—nicotine dependence	0.000126	0.000921	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—OPRM1—nicotine dependence	0.000111	0.000815	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGD1—nicotine dependence	0.000111	0.000813	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—DRD2—nicotine dependence	0.000109	0.000798	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—OPRM1—nicotine dependence	0.000101	0.00074	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—OPRM1—nicotine dependence	0.0001	0.000733	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGD1—nicotine dependence	9.99e-05	0.000732	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—DRD2—nicotine dependence	9.88e-05	0.000725	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—OPRM1—nicotine dependence	9.87e-05	0.000724	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGD1—nicotine dependence	9.85e-05	0.000722	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKR1B10—nicotine dependence	9.8e-05	0.000718	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TAS2R16—nicotine dependence	9.61e-05	0.000705	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—WASF2—nicotine dependence	9.35e-05	0.000686	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—OPRM1—nicotine dependence	9.08e-05	0.000666	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—WASF1—nicotine dependence	8.97e-05	0.000658	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—OPRM1—nicotine dependence	8.96e-05	0.000657	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKR1B10—nicotine dependence	8.82e-05	0.000647	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKR1B10—nicotine dependence	8.7e-05	0.000638	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—OPRM1—nicotine dependence	8.08e-05	0.000592	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—DRD2—nicotine dependence	8.03e-05	0.000589	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—OPRM1—nicotine dependence	7.55e-05	0.000554	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGD1—nicotine dependence	7.54e-05	0.000553	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—DRD2—nicotine dependence	7.29e-05	0.000535	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—DRD2—nicotine dependence	7.23e-05	0.00053	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—DRD2—nicotine dependence	7.13e-05	0.000523	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—WASF2—nicotine dependence	6.9e-05	0.000506	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—OPRM1—nicotine dependence	6.86e-05	0.000503	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKR1B10—nicotine dependence	6.66e-05	0.000488	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—WASF1—nicotine dependence	6.62e-05	0.000485	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—DRD2—nicotine dependence	6.57e-05	0.000481	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—DRD2—nicotine dependence	6.48e-05	0.000475	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—WASF2—nicotine dependence	6.22e-05	0.000456	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—WASF2—nicotine dependence	6.13e-05	0.00045	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—OPRM1—nicotine dependence	5.96e-05	0.000437	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—WASF1—nicotine dependence	5.96e-05	0.000437	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—WASF1—nicotine dependence	5.88e-05	0.000431	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—DRD2—nicotine dependence	5.84e-05	0.000428	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—OPRM1—nicotine dependence	5.37e-05	0.000393	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—OPRM1—nicotine dependence	5.29e-05	0.000388	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—WASF2—nicotine dependence	4.69e-05	0.000344	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—WASF1—nicotine dependence	4.5e-05	0.00033	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP2A7—nicotine dependence	4.32e-05	0.000317	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—DRD2—nicotine dependence	4.31e-05	0.000316	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—OPRM1—nicotine dependence	4.05e-05	0.000297	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—DRD2—nicotine dependence	3.88e-05	0.000284	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—DRD2—nicotine dependence	3.83e-05	0.000281	CbGpPWpGaD
